Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 223859 | 3.91 |
09:34 ET | 29893 | 3.895 |
09:36 ET | 16043 | 3.885 |
09:38 ET | 49780 | 3.88 |
09:39 ET | 14210 | 3.855 |
09:41 ET | 6706 | 3.86 |
09:43 ET | 11913 | 3.885 |
09:45 ET | 1924 | 3.88 |
09:48 ET | 158057 | 3.865 |
09:50 ET | 19273 | 3.85 |
09:52 ET | 5200 | 3.845 |
09:54 ET | 10891 | 3.84 |
09:56 ET | 186394 | 3.83 |
09:57 ET | 11421 | 3.84 |
09:59 ET | 4402 | 3.84 |
10:01 ET | 9937 | 3.84 |
10:03 ET | 1487 | 3.84 |
10:06 ET | 957 | 3.835 |
10:08 ET | 28758 | 3.835 |
10:10 ET | 19038 | 3.825 |
10:12 ET | 561 | 3.825 |
10:14 ET | 11756 | 3.825 |
10:15 ET | 65951 | 3.795 |
10:17 ET | 59907 | 3.785 |
10:19 ET | 36748 | 3.785 |
10:21 ET | 60182 | 3.7801 |
10:24 ET | 36326 | 3.8 |
10:26 ET | 550 | 3.795 |
10:28 ET | 736 | 3.7971 |
10:30 ET | 1194 | 3.795 |
10:32 ET | 43948 | 3.785 |
10:33 ET | 7986 | 3.785 |
10:35 ET | 14285 | 3.7885 |
10:37 ET | 28926 | 3.785 |
10:39 ET | 48685 | 3.77 |
10:42 ET | 4442 | 3.775 |
10:44 ET | 24511 | 3.78 |
10:46 ET | 31106 | 3.7851 |
10:48 ET | 6892 | 3.785 |
10:50 ET | 70761 | 3.785 |
10:51 ET | 5829 | 3.7811 |
10:53 ET | 15927 | 3.775 |
10:55 ET | 1700 | 3.775 |
10:57 ET | 547 | 3.77 |
11:00 ET | 1322 | 3.77 |
11:02 ET | 3932 | 3.77 |
11:04 ET | 58091 | 3.765 |
11:06 ET | 8529 | 3.765 |
11:08 ET | 13000 | 3.7601 |
11:09 ET | 74967 | 3.745 |
11:11 ET | 6350 | 3.745 |
11:13 ET | 25810 | 3.755 |
11:15 ET | 5101 | 3.7549 |
11:18 ET | 5856 | 3.76 |
11:20 ET | 31197 | 3.765 |
11:22 ET | 9693 | 3.755 |
11:24 ET | 200 | 3.7566 |
11:26 ET | 13826 | 3.74 |
11:27 ET | 13680 | 3.74 |
11:29 ET | 72383 | 3.765 |
11:31 ET | 35610 | 3.765 |
11:33 ET | 10456 | 3.77 |
11:36 ET | 13137 | 3.76 |
11:38 ET | 5100 | 3.7588 |
11:40 ET | 5339 | 3.7501 |
11:42 ET | 91863 | 3.755 |
11:44 ET | 49840 | 3.755 |
11:45 ET | 14485 | 3.76 |
11:47 ET | 4171 | 3.755 |
11:49 ET | 6251 | 3.7512 |
11:51 ET | 4827 | 3.76 |
11:54 ET | 3490 | 3.755 |
11:56 ET | 12343 | 3.76 |
11:58 ET | 3742 | 3.755 |
12:00 ET | 2583 | 3.76 |
12:02 ET | 33611 | 3.765 |
12:03 ET | 2709 | 3.765 |
12:05 ET | 6854 | 3.765 |
12:07 ET | 7207 | 3.765 |
12:09 ET | 5078 | 3.77 |
12:12 ET | 11554 | 3.78 |
12:14 ET | 15756 | 3.785 |
12:16 ET | 10559 | 3.785 |
12:18 ET | 6540 | 3.785 |
12:20 ET | 3655 | 3.785 |
12:21 ET | 66772 | 3.79 |
12:23 ET | 1750 | 3.785 |
12:25 ET | 900 | 3.785 |
12:27 ET | 2976 | 3.79 |
12:30 ET | 14159 | 3.8 |
12:32 ET | 10542 | 3.8 |
12:34 ET | 50026 | 3.815 |
12:36 ET | 8652 | 3.815 |
12:38 ET | 15088 | 3.805 |
12:39 ET | 624 | 3.81 |
12:41 ET | 23600 | 3.805 |
12:43 ET | 21619 | 3.805 |
12:45 ET | 2389 | 3.81 |
12:48 ET | 1788 | 3.805 |
12:50 ET | 3662 | 3.805 |
12:52 ET | 8398 | 3.82 |
12:54 ET | 70410 | 3.805 |
12:56 ET | 9836 | 3.815 |
12:57 ET | 2500 | 3.815 |
12:59 ET | 4945 | 3.82 |
01:01 ET | 3179 | 3.815 |
01:03 ET | 37670 | 3.82 |
01:06 ET | 2176 | 3.815 |
01:08 ET | 3063 | 3.82 |
01:10 ET | 9654 | 3.825 |
01:12 ET | 5200 | 3.825 |
01:14 ET | 16487 | 3.815 |
01:15 ET | 13071 | 3.825 |
01:17 ET | 2814 | 3.82 |
01:19 ET | 8342 | 3.83 |
01:21 ET | 968 | 3.825 |
01:24 ET | 4709 | 3.825 |
01:26 ET | 4324 | 3.825 |
01:28 ET | 4411 | 3.825 |
01:30 ET | 4908 | 3.825 |
01:32 ET | 1500 | 3.825 |
01:33 ET | 35396 | 3.815 |
01:35 ET | 58565 | 3.83 |
01:37 ET | 1581 | 3.83 |
01:39 ET | 2715 | 3.825 |
01:42 ET | 5075 | 3.825 |
01:44 ET | 1043 | 3.825 |
01:46 ET | 1900 | 3.825 |
01:48 ET | 2150 | 3.8225 |
01:50 ET | 2100 | 3.825 |
01:51 ET | 4128 | 3.825 |
01:53 ET | 4057 | 3.83 |
01:55 ET | 4779 | 3.825 |
01:57 ET | 2176 | 3.825 |
02:00 ET | 7879 | 3.82 |
02:02 ET | 34950 | 3.815 |
02:04 ET | 3759 | 3.81 |
02:06 ET | 115601 | 3.805 |
02:08 ET | 3380 | 3.805 |
02:09 ET | 1229 | 3.8025 |
02:11 ET | 33129 | 3.805 |
02:13 ET | 32860 | 3.81 |
02:15 ET | 6079 | 3.805 |
02:18 ET | 30997 | 3.83 |
02:20 ET | 6842 | 3.825 |
02:22 ET | 11819 | 3.82 |
02:24 ET | 1784 | 3.815 |
02:26 ET | 146 | 3.815 |
02:27 ET | 80679 | 3.815 |
02:29 ET | 2599 | 3.815 |
02:31 ET | 4349 | 3.815 |
02:33 ET | 8234 | 3.815 |
02:36 ET | 43830 | 3.81 |
02:38 ET | 133456 | 3.815 |
02:40 ET | 3700 | 3.815 |
02:42 ET | 1794 | 3.815 |
02:44 ET | 5415 | 3.81 |
02:45 ET | 8909 | 3.81 |
02:47 ET | 7417 | 3.815 |
02:49 ET | 5791 | 3.81 |
02:51 ET | 5744 | 3.81 |
02:54 ET | 177551 | 3.82 |
02:56 ET | 58011 | 3.815 |
02:58 ET | 3388 | 3.81 |
03:00 ET | 3914 | 3.815 |
03:02 ET | 6830 | 3.81 |
03:03 ET | 143472 | 3.815 |
03:05 ET | 67651 | 3.8 |
03:07 ET | 10670 | 3.795 |
03:09 ET | 8903 | 3.795 |
03:12 ET | 13522 | 3.79 |
03:14 ET | 9305 | 3.795 |
03:16 ET | 15332 | 3.795 |
03:18 ET | 79014 | 3.815 |
03:20 ET | 3998 | 3.815 |
03:21 ET | 19588 | 3.815 |
03:23 ET | 21265 | 3.805 |
03:25 ET | 60934 | 3.815 |
03:27 ET | 24789 | 3.805 |
03:30 ET | 3537 | 3.805 |
03:32 ET | 12232 | 3.8 |
03:34 ET | 148322 | 3.8086 |
03:36 ET | 14218 | 3.805 |
03:38 ET | 10506 | 3.805 |
03:39 ET | 20553 | 3.81 |
03:41 ET | 58980 | 3.83 |
03:43 ET | 26016 | 3.83 |
03:45 ET | 12462 | 3.83 |
03:48 ET | 22718 | 3.825 |
03:50 ET | 30793 | 3.83 |
03:52 ET | 152201 | 3.81 |
03:54 ET | 70834 | 3.805 |
03:56 ET | 148288 | 3.805 |
03:57 ET | 33137 | 3.81 |
03:59 ET | 210424 | 3.81 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.3B | -11.0x | --- |
Vera Therapeutics Inc | 2.3B | -20.3x | --- |
Dyne Therapeutics Inc | 2.4B | -7.0x | --- |
Rocket Pharmaceuticals Inc | 2.1B | -7.9x | --- |
Janux Therapeutics Inc | 2.4B | -38.5x | --- |
CG Oncology Inc | 2.0B | -26.6x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.3B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -11.0x |
Price/Sales (TTM) | 4,345.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.